Taysha Gene Therapies (TSHA) Enterprise Value (QoQ) (2020 - 2026)

Taysha Gene Therapies (TSHA) Enterprise Value (QoQ) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Taysha Gene Therapies 1.94 Bn 1.94 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2026 -64.38%
Mar 31, 2026 13.48%
Dec 31, 2025 -7.53%
Sep 30, 2025 4.92%
Jun 30, 2025 -167.60%
Mar 31, 2025 16.09%
Dec 31, 2024 11.79%
Sep 30, 2024 8.69%
Jun 30, 2024 -39.19%
Mar 31, 2024 13.82%
Dec 31, 2023 12.11%
Sep 30, 2023 -264.39%
Jun 30, 2023 28.92%
Sep 30, 2022 44.23%
Jun 30, 2022 33.27%
Mar 31, 2022 34.58%
Dec 31, 2021 20.73%
Sep 30, 2021 3.02%
Jun 30, 2021 13.69%
Mar 31, 2021 8.98%